x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

MedTech Global Insights

What"s next in the future of health? Welcome to MedTech Global Insights, the podcast dedicated to uncovering the most disruptive technologies and brilliant minds in the medical field. Whether you"re an industry professional, investor, or simply curious, subscribe for your dose of cutting-edge information and expert commentary.

science life sciences

All Episodes

02:08

US FDA's Cyber Wall: Pure Global on MedTech...

MedTech Global Insights ·

2026/02/03

This week on MedTech Global Insights, we dissect the wave of "Refuse to Accept" letters from the US FDA that are derailing market entry plans. As the agency fully enforces its new cybersecurity mandates, many MedTech companies are finding their submissions unexpectedly rejected, causing costly delays and forcing a rethink of their entire regulatory strategy. We explore the critical gap between existing technical documentation and the FDA's stringent new requirements. This episode moves beyond the

en

02:08

Pure Global: US MedTech's Supply Chain Data Crisis

MedTech Global Insights ·

2026/02/02

The game has changed for MedTech approvals. Following a recent FDA alert, data from third-party testing labs is now under intense scrutiny, creating a hidden barrier to market access. This episode of MedTech Global Insights explores the rising threat of unreliable partner data and what it means for your regulatory submissions. We dive into the silent rejection wave hitting unprepared companies. One diagnostics firm recently had its 510(k) submission derailed, not by a flaw in their device, but by

en

01:59

USA Quality Systems: Pure Global on the FDA's Great...

MedTech Global Insights ·

2026/02/01

This week, we dissect the FDA's landmark final rule, which replaces the decades-old Quality System Regulation (QSR) with the new Quality Management System Regulation (QMSR). This significant move aligns US requirements with the global ISO 13485 standard, representing a major strategic shift for every medical device manufacturer selling in the United States.We explore how this transition moves beyond simple documentation changes to embrace a fully risk-based quality philosophy. Learn about the

en

02:04

Europe's IVDR Deadline Illusion: A Pure Global Briefing

MedTech Global Insights ·

2026/01/31

The European Commission has proposed another extension to the IVDR transition deadlines, offering a potential lifeline to the diagnostics industry. However, this relief comes with a critical catch that could mislead unprepared manufacturers into a false sense of security. We uncover the hidden details and strategic urgency behind the headlines. This episode dissects why this is not a simple delay but a strategic reset with a new, urgent deadline. We explore the severe shortage of Notified Body

en

01:52

U.S. AI Diagnostics: Pure Global on the FDA's Hidden...

MedTech Global Insights ·

2026/01/30

The U.S. FDA has just released new draft guidance on AI-powered Clinical Decision Support (CDS) software, sending a wave of uncertainty across the MedTech industry. This episode of MedTech Global Insights breaks down what this sudden shift means for innovators, investors, and regulatory professionals. We dissect the key changes and explore why many tools previously considered low-risk may now face stringent regulatory oversight.We explore the new focus on algorithmic transparency and what it means

en

01:51

EU AI Diagnostics: The New Compliance Crisis | Pure...

MedTech Global Insights ·

2026/01/29

This week on MedTech Global Insights, we dissect the latest regulatory tremor from the European Union. A new draft guidance on AI-powered medical software has just been released, and it’s sending ripples through the industry by fundamentally changing the rules for post-market surveillance and model transparency. We explore what this means for innovators and established players alike, moving beyond the headlines to analyze the operational and financial burdens of proving AI model stability in the

en

02:03

EU AI Act's Hidden Test: Pure Global on MedTech's New...

MedTech Global Insights ·

2026/01/28

The EU's AI Act is creating a new, complex layer of regulation for MedTech companies, especially for those with AI-powered software. A device fully compliant with the Medical Device Regulation (MDR) could now be deemed a "high-risk AI system," demanding an entirely new set of evidence and documentation for market access.This episode of MedTech Global Insights explores this dual compliance challenge. We break down the specific new obligations the AI Act places on medical device manufacturers, from

en

02:11

USA Device Cybersecurity: Pure Global on FDA's...

MedTech Global Insights ·

2026/01/27

This week on MedTech Global Insights, we dissect the FDA's aggressive new enforcement on medical device cybersecurity. As regulators begin to treat digital vulnerabilities as critical safety failures, the rules for market access have fundamentally changed. We explore what this means for manufacturers, from new pre-market submission requirements to the severe consequences of post-market negligence. Our discussion centers on a recent case where a cardiovascular device firm faced regulatory action for

en

01:56

US FDA's Health App Crackdown: The Compliance Trap |...

MedTech Global Insights ·

2026/01/26

This week, we dissect the FDA's newly released guidance on General Wellness and Clinical Decision Support software. This isn't just a minor update; it's a critical clarification that redraws the line between a simple health app and a regulated medical device, forcing many developers to re-evaluate their entire business strategy. MedTech Global Insights explores the direct impact of these changes. We uncover the specific criteria the FDA is now using to scrutinize AI and software-based health

en

02:18

Pure Global: USA's New AI Device Rules - A Speed Trap?

MedTech Global Insights ·

2026/01/25

This week, we dissect the FDA's bombshell draft guidance on AI/ML-enabled medical devices. The new framework for Predetermined Change Control Plans (PCCPs) promises faster innovation but hides a complex web of new requirements. This episode unpacks what this means for manufacturers, from agile startups to global giants, and analyzes the strategic pivot required to leverage this new pathway instead of being trapped by it. A well-funded AI diagnostic startup in California celebrated the new FDA

en

02:11

USA's Code Red Compliance: Pure Global on Device...

MedTech Global Insights ·

2026/01/24

The U.S. FDA has just escalated cybersecurity from a guideline to a mandatory gateway for market access. This episode of MedTech Global Insights unpacks the finalized guidance and its immediate, seismic impact on manufacturers of connected medical devices worldwide. We explore the immense operational challenges of new requirements like the Software Bill of Materials (SBOM) and proactive post-market threat monitoring. Discover the real-world impact through the case of a successful European infusion

en

01:43

Pure Global: US MedTech's Urgent Cyber Mandate

MedTech Global Insights ·

2026/01/23

This week, we dissect the FDA's aggressive new stance on medical device cybersecurity, a shift causing major disruptions for manufacturers. What was once a recommendation is now a strict mandate, making cybersecurity documentation a primary reason for submission rejections and costly market entry delays.We explore how this regulatory crackdown moves beyond simple compliance to demand a proactive, lifecycle-long security strategy. This is not just an IT problem anymore; it is a critical business

en

01:57

UK AI Diagnostics: Pure Global on MHRA's Risky New...

MedTech Global Insights ·

2026/01/22

This week on MedTech Global Insights, we dissect the UK MHRA's groundbreaking new accelerated approval pathway for AI-powered medical devices. This policy shift aims to make post-Brexit Britain a hub for digital health innovation, but what does it really mean for manufacturers on the ground?We explore the real-world implications through the lens of the first company to navigate this new process. Discover the potential pitfalls and strategic adjustments you must consider to capitalize on this

en

02:06

EU's MDR Relief & Notified Body Rift: A Pure Global...

MedTech Global Insights ·

2026/01/21

The European Union's notoriously complex MDR and IVDR regulations have been a major challenge for the MedTech industry. Last week, the European Commission unveiled a proposal to simplify the rules, offering a glimmer of hope for manufacturers. However, the situation is complicated by a new position paper from the Notified Bodies (Team-NB), who are raising concerns about the proposed changes.This episode of MedTech Global Insights dives into this critical regulatory development. We explore the

en

01:47

Pure Global: Europe's MedTech & The Post-Market Surprise

MedTech Global Insights ·

2026/01/20

Many MedTech companies breathe a sigh of relief after achieving their European CE mark, believing the hardest part is over. But a recent guidance document from the EU's Medical Device Coordination Group (MDCG) on post-market surveillance is proving that the finish line has moved. This new interpretation demands a more dynamic and data-intensive approach to monitoring devices, catching many manufacturers off-guard.In this episode, we break down what this enhanced scrutiny really means for your

en

01:56

USA LDT Crackdown: Pure Global on the New FDA Reality

MedTech Global Insights ·

2026/01/19

The FDA has finalized its groundbreaking rule, ending its long-standing enforcement discretion for Laboratory Developed Tests (LDTs). This episode unpacks this monumental shift, explaining how thousands of clinical laboratories across the United States will now fall under full medical device regulations, fundamentally changing the diagnostics landscape. We break down the four-year, five-stage transition plan mandated by the FDA. From adverse event reporting to full premarket approval, we discuss the

en

01:42

Pure Global: SF MedTech's Post-JPM Deal Shockwaves

MedTech Global Insights ·

2026/01/18

This week, we dissect the massive $3.7 billion acquisition of Axonics by Boston Scientific. This deal, announced during the landmark J.P. Morgan Healthcare Conference, signals a major shift in the MedTech M&A landscape and sets a new competitive dynamic in the sacral neuromodulation market.We explore the strategic thinking behind the acquisition, analyzing why Axonics became such an attractive target and what this means for Medtronic's long-held dominance. This episode provides critical insights

en

01:55

Pure Global: US Digital Health's TEMPO Pivot -...

MedTech Global Insights ·

2026/01/17

The U.S. FDA just launched the TEMPO pilot program, a groundbreaking "regulatory-light" pathway for digital health devices. This episode of MedTech Global Insights unpacks what this major shift means for manufacturers, how it ties regulatory approval directly to reimbursement, and why the game is changing for chronic disease management technologies. We look at the case of Ceribell, a company that recently secured three FDA approvals in rapid succession. Their platform-based approach is a

en

01:43

USA's Digital Health TEMPO Trap: A Pure Global...

MedTech Global Insights ·

2026/01/16

In this episode of MedTech Global Insights, we dissect two monumental shifts in the U.S. regulatory landscape happening right now. The FDA is rolling out its new TEMPO pilot program, offering a potential "regulatory light" pathway for digital health technologies. This could revolutionize market access for AI, machine learning, and chronic disease management devices. However, this opportunity is on a collision course with a major compliance deadline. In just a few weeks, the new, stricter Quality

en

01:57

US Digital Health: Pure Global on the FDA's...

MedTech Global Insights ·

2026/01/15

Last week, the US FDA announced a major shift in policy, easing regulations for low-risk digital health products and wearables. This move, revealed at CES 2026, aims to spur innovation by removing barriers for technologies that 'simply provide information' for general wellness.But this new freedom comes with a hidden challenge. The line between an unregulated wellness device and a regulated medical device is now more critical, and blurrier, than ever. This episode of MedTech Global Insights

en

239 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter